CML HealthCare Licenses Rights to XDx's AlloMap | GenomeWeb

NEW YORK (GenomeWeb News) – CML HealthCare and XDx jointly announced today that CML has licensed exclusive rights to market XDx's AlloMap test initially in Ontario, Canada but with an option to extend the rights across the country.

Mississauga, Ontario-based CML, a publicly held diagnostic services provider, expects to begin offering the test later this summer. Financial and other terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.